Flotek Industries, Inc. — 2019 Form 10-K Summary
Business context and reporting period
Fiscal year ended December 31, 2019; the filing also reports fourth-quarter results. Flotek is now focused on Energy Chemistry Technologies (ECT), which develops and supplies specialty chemistry and related services for oil and gas drilling, completion, and production. The Consumer and Industrial Chemistry Technologies (CICT) business was sold to ADM effective February 28, 2019 and is reported as discontinued operations.
Financial performance and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue from continuing operations | $119.4 million | $177.8 million |
| Operating loss | $76.6 million | $69.8 million |
| Operating margin | (64.2)% | (39.3)% |
| Loss from continuing operations | $76.7 million | $73.4 million |
| Income from discontinued operations, net of tax | $44.5 million | $2.7 million |
| Net loss | $32.3 million | $70.7 million |
| Cash used in operating activities | $18.8 million | $20.8 million |
- Revenue declined 32.9% year over year. Management cited product mix, volatile U.S. onshore activity, sales-team turnover, and the shift toward selling directly to oil and gas companies rather than through oilfield service companies.
- Operating expenses excluding depreciation and amortization fell 6.6%, but rose to 125.0% of revenue from 89.9%, reflecting the sharp revenue contraction and costs including the terpene supply commitment loss, inventory charges, lower plant utilization, and a contract termination charge.
- Fourth-quarter revenue was $19.5 million; operating loss was $36.6 million and loss from continuing operations was $37.1 million. The filing does not separately quantify all drivers of the quarter’s operating loss.
- At year-end, cash and cash equivalents were $100.6 million, with an additional $0.7 million of restricted cash. Debt was zero after repayment and termination of the PNC credit facility in March 2019. Total assets were $231.8 million and stockholders’ equity was $173.3 million.
- Capital expenditures were $2.4 million. Cash from investing activities was $166.9 million, principally reflecting business-sale proceeds; cash used in financing activities was $50.0 million, principally debt repayment.
Material changes and unusual items
- Flotek sold CICT to ADM for $175.0 million in cash consideration. The company recorded a $64.2 million gain on sale in discontinued operations; that gain substantially reduced the reported consolidated net loss but did not change the continuing-operations loss.
- In February 2020, an arbitrator awarded ADM the full $4.1 million disputed working-capital adjustment, reducing the sale gain as of December 31, 2019.
- The company recognized a loss on the terpene supply agreement amendment. A February 2020 amendment reduced minimum purchase quantities and set a fixed 2020 price; Flotek made a one-time $15.8 million payment, recorded in accrued liabilities at year-end. The filing reports a $72.0 million remaining minimum commitment at December 31, 2019, before describing the amendment.
- Inventory reserves increased to $5.7 million from $2.1 million, including a $4.4 million reserve for excess terpene. The allowance for doubtful accounts rose to 8.9% of gross receivables from 3.1%.
- The company adopted lease accounting guidance in 2019 and recognized operating lease right-of-use assets and liabilities. Year-end operating and finance lease liabilities totaled approximately $17.7 million.
Outlook, risks, and contingencies
- Management expected further softening in the U.S. onshore oil and gas market in 2020, while believing greater adoption of specialty chemicals could offset lower activity. It planned to rebuild sales channels, focus on customer economics, and use analytics to demonstrate product performance.
- Management forecast 2020 maintenance capital spending of $2 million to $4 million and had no specific growth capital projects committed. It was evaluating uses of sale proceeds, including growth opportunities, share repurchases, and a possible special distribution; no distribution or other deployment was committed.
- Principal risks include dependence on oil and gas activity and commodity prices, customer concentration (the three largest customers represented 40% of revenue in 2019), supplier concentration for citrus terpene, execution of the sales transition, raw-material costs, and the company’s ability to return to profitability. The filing also identifies coronavirus-related uncertainty as a potential risk.
- The company reported no material pending litigation expected to affect its financial position, results, or liquidity. It recorded a $1.8 million potential IRS employment-tax liability related to CEO compensation; affiliated companies agreed to indemnify Flotek, supported by a personal guaranty, and the receivable was offset against severance payable.
- Management and the independent auditor concluded that internal control over financial reporting was effective as of year-end; the auditor issued an unqualified opinion on the financial statements and controls.
Important facts for investors to verify
- Updated terpene purchase commitments, the $15.8 million amendment payment, and the expected cost and supply implications after the February 2020 amendment.
- The final accounting and cash impact of the $4.1 million ADM working-capital award and other sale-related escrow balances.
- Whether management’s specialty-chemistry adoption and sales-channel initiatives can stabilize revenue and improve margins amid weaker market activity.
- Cash burn, working-capital requirements, and the ability to meet lease and other contractual obligations without recurring operating cash generation.
- Customer concentration, receivable collectability, and the company’s dependence on its terpene supplier.
- Potential dilution from outstanding equity awards and any future capital deployment or shareholder distribution.